Telephone OncoGériatric Followed in the Management of Elderly Patients Treated for Cancer or Haematological Malignancy

NCT02583035 | Completed DMC

• 1 other identifier: TelOG
• Study Type: interventional
• Target: 131
• Locations: 1 country
• Sites: 5

Brief Summary

There are no recommendations and few studies on the monitoring of fragile patients in the oncological treatment, both on the organizational arrangements on its interest in the prevention of functional deterioration of the patient and adaptation of the potential cancer treatment. The oncogériatrique evaluation being time-consuming, requiring the movement of these more or less frail elderly patients, it seems difficult to envisage repeated and systematic standardized geriatric assessments during cancer treatment. Geriatric fragility can be detected by telephone. Craven et al. has already assessed the telephone follow-up by a nurse in patients treated for cancer, but with the aim to detect toxicities of cancer treatment, patients are not very old (mean age 64.8 years). External evaluation by the nurse coordinator of UCOG (Coordination Unit in geriatric oncology) not knowing the patients included avoids bias of subjectivity in the interrogation. However the telephone monitoring, with the aim to evaluate the evolution of geriatric frailty, has not been specifically studied in the elderly population treated for cancer, while taking oncology load. The investigators wish to study the feasibility and validity of telephone follow-up which could eventually be used routinely to identify patients requiring further medical consultation oncogériatrique.

Conditions

Cancer; Hematologic Malignancy

Keywords

cancer; geriatric

Outcome Measures

Primary Outcomes (6)

• Memory on the Mini Mental Scale

  3 months after inclusion

• Falls on the number of falls

  3 months after inclusion

• Pain on the EVS (verbal scale) scale

  3 months after inclusion

• Autonomy on the ADL (activities of daily living) score

  3 months after inclusion

• Pain on the EN (numericale scale) scale

  3 months after inclusion

• Autonomy on the IADL (The Lawton Instrumental Activities of Daily Living Scale ) score

  3 months after inclusion

Study Arms (1)

Nurse telephone contact

OTHER

3 days of consultation, telephone follow-up of the patient by the nurse coordinator of the Geriatric Oncology Unit to validate

Other: Nurse telephone contact

Interventions

Nurse telephone contact OTHER

Nurse will contact patient 3 days before consultation

Nurse telephone contact

Eligibility Criteria

• Age: 70 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Older Adult (65+)

You may qualify if:

• Patients 70 years and older with cancer or hematologic malignancies;
• Faced benefit from cancer treatment (systemic treatment, curative radiotherapy) in one of the clinical sites;
• Addressed in onco-gériatric consultation in the usual routine care sector;
• Mastery of the French language;
• Patient affiliated to the social security system;
• Patient has given its written consent.

You may not qualify if:

• Life expectancy \<3 months
• Inability to communicate by telephone (deafness, speech disorder, ..)
• Inability collection of written consent
• Group 4 SiO (International Society of Geriatric Oncology), Performance status (PS) 4
• initial MMSE (Mini-Mental State Examination) \<18/30
• oncological treatment envisaged: analgesic radiotherapy or exclusive decompressive, brain radiation therapy in toto
• Patient under guardianship

Sponsors & Collaborators

• Centre Francois Baclesse: lead

Study Sites (5)

Centre Hospitalier

Bayeux, France

Location

CHU

Caen, 14033, France

Location

Centre François Baclesse

Caen, 14400, France

Location

Centre Hospitalier

Dieppe, France

Location

Centre Hospitalier du Havre

Le Havre, France

Location

MeSH Terms

Conditions

Neoplasms; Hematologic Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by Site; Hematologic Diseases; Hemic and Lymphatic Diseases

Study Officials

• Bérengère Beauplet, MD

  University Hospital, Caen

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: OTHER
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 17, 2015
• First Posted: October 21, 2015
• Study Start: February 1, 2015
• Primary Completion: February 16, 2018
• Study Completion: May 14, 2018
• Last Updated: January 16, 2019

Record last verified: 2019-01

Locations

FR (5)